Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Influenza Vaccination on Systemic Inflammation in Stable Coronary Artery Disease (Delayed-Start Pilot)
2024-514543-28-00Phase 2Authorised
- Sponsor
- CHRU Tours
- Start
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Vaxigrip in influenza and coronary arteriosclerosis (2 arms), sponsored by CHRU Tours. Primary endpoint: Change in plasma high-sensitivity C-reactive protein (hsCRP) at 1 month. Planned start Sep 2024; status: authorised.
02
Drugs
Vaxigrip
03
Conditions
influenzacoronary arteriosclerosis
Beyond the preview
Go deeper on 2024-514543-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514543-28-00.